{"entity":{"id":"aptose","kind":"company","name":"Aptose Biosciences","aka":["Aptose Biosciences Inc.","Aptose"],"tldr":"Aptose is a San Diego and Toronto company developing tuspetinib, an oral kinase inhibitor acting on FLT3, SYK, JAK and other targets, for acute myeloid leukaemia in combination with venetoclax and azacitidine.","summary":"Aptose Biosciences, listed on Nasdaq and the Toronto exchange, develops kinase inhibitors for blood cancers. Its lead, tuspetinib (HM43239), licensed from Hanmi, inhibits FLT3, SYK, JAK1/2 and other kinases and is being combined with venetoclax and azacitidine in newly diagnosed acute myeloid leukaemia after single-agent responses in relapsed disease; an earlier candidate, luxeptinib, was deprioritised. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.aptose.com"},{"label":"ClinicalTrials.gov: trials led by Aptose Biosciences","url":"https://clinicaltrials.gov/search?lead=Aptose%20Biosciences"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml"],"sections":["targeted-therapy"],"technologies":[],"targets":["flt3"],"drugs":["venetoclax","azacitidine","tuspetinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.aptose.com","stage":"public","investors":[],"funding":[]},"route":"/companies/aptose/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"tuspetinib","kind":"drug","name":"Tuspetinib","route":"/drugs/tuspetinib/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"trial":[{"id":"nct03850574","kind":"trial","name":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct03850574/"}]}}